Ershov F I, Sumin V I, Saĭitkulov A M, Baram N I, Tazulakhova E B, Ismailov A I
Antibiot Khimioter. 1992 Jan;37(1):29-32.
The pharmacokinetics of PHL-6 and interferon synthesis dynamic in the target organs (tissues) of mice were studied during its and intraperitoneal administration. In the experimental setting, there was a direct correlation between the interferon production in the murine organs with single PHL-6 and distribution of 14C PHL-6. The highest radioactivity with its oral administration was detected in the liver and intestine. Interferon was actively synthesized in the intestine, liver and serum, showing the levels of 20000, 1024-2048 and 512-1024 IU/ml, respectively. The prolonged action of the drug was in good agreement with the low PHL-6 excretion from the body. It was also shown that almost the whole radiation dose 1 (greater than 98%) was excreted with feces and urine after single and chronic administrations of uniformly labeled PHL-6 which proved important clinical drug use.
研究了PHL-6腹腔注射给药后在小鼠靶器官（组织）中的药代动力学及干扰素合成动态。在实验条件下，小鼠器官中单次注射PHL-6后产生的干扰素与14C-PHL-6的分布之间存在直接相关性。口服给药后，肝脏和肠道中检测到最高放射性。干扰素在肠道、肝脏和血清中被积极合成，水平分别为20000、1024 - 2048和512 - 1024 IU/ml。药物的长效作用与PHL-6从体内的低排泄量相符。还表明，单次和长期给予均匀标记的PHL-6后，几乎全部辐射剂量1（大于98%）经粪便和尿液排出，这证明了该药物在临床上的重要用途。
